Table 1.
The baseline characteristics in patients based on PD-L1 expression level.
Table 2.
Clinical outcomes of pembrolizumab monotherapy according to PD-L1 expression level.
Fig 1.
Time to treatment failure of pembrolizumab: the tumor proportion score 90–100% cohort versus the tumor proportion score 50–89% cohort.
Panel A shows the Kaplan–Meier survival curves for the time to treatment failure according to the programed death ligand-1 expression levels for the tumor proportion score 90–100% cohort versus the tumor proportion score 50–89% cohort. Panel B shows the Kaplan–Meier survival curves for time to treatment failure before and after 120 days according to the programed death ligand-1 expression levels in landmark analyses. Hazard ratios are for the tumor proportion score 90–100% cohort versus the tumor proportion score 50–89% cohort. The hazard ratios, 95% confidence intervals, and p-values were calculated using univariate Cox regression analysis. Cross marks represent data censored at the last time the patient was known to be alive. Abbreviations: HR, hazard ratio; TPS, tumor proportion score.
Fig 2.
Exploratory subgroup analyses of time to treatment failure: The tumor proportion score 90–100% cohort versus the tumor proportion score 50–89% cohort.
Hazard ratios for the time to treatment failure in the tumor proportion score 90–100% cohort versus the tumor proportion score 50–89% cohort. The hazard ratios, 95% confidence intervals, and p-values for each key subgroup were calculated using univariate Cox regression analysis. The response to pembrolizumab was defined as complete and partial responses assessed by the investigator according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Early irAE was defined as irAE that occurred within 3 weeks after commencing pembrolizumab therapy. Abbreviations: HR, hazard ratio; TPS, tumor proportion score; ECOG PS, Eastern Cooperative Oncology Group performance status; irAE, immune-related adverse event.
Table 3.
Immune-related adverse events after commencing pembrolizumab therapy.